Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions.
作者信息
Jabbour Richard J, Tanaka Akihito, Capranzano Piera, Cortese Bernardo, Lesiak Maciej, Testa Luca, Gatto Pamela, Suarez de Lezo José, Mattesini Alessio, Geraci Salvatore, Ielasi Alfonso, Diletti Roberto, Capodanno Davide, Buccheri Dario, Iwanczyk Sylwia, Bedogni Francesco, Tchetche Didier, Di Mario Carlo, Caramanno Giuseppe, Van Mieghem Nicolas M, Tamburino Corrado, Colombo Antonio, Latib Azeem
出版信息
JACC Cardiovasc Interv. 2017 Apr 10;10(7):743-745. doi: 10.1016/j.jcin.2017.01.038.
PMID:28385415
Abstract
摘要
相似文献
1
Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions.
JACC Cardiovasc Interv. 2017 Apr 10;10(7):743-745. doi: 10.1016/j.jcin.2017.01.038.
2
The future of bioresorbable vascular scaffolds: niche or workhorse devices?
Coron Artery Dis. 2017 Sep;28(6):449-451. doi: 10.1097/MCA.0000000000000513.
3
Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
JACC Cardiovasc Interv. 2017 Mar 27;10(6):560-568. doi: 10.1016/j.jcin.2016.12.013. Epub 2017 Mar 1.
4
Polymeric bioresorbable coronary scaffolds: the hype is over, but the dream lives on.
EuroIntervention. 2018 Jan 20;13(13):1506-1509. doi: 10.4244/EIJV13I13A242.
5
Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.
BMC Cardiovasc Disord. 2018 May 10;18(1):92. doi: 10.1186/s12872-018-0811-7.
6
Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?
Arch Cardiovasc Dis. 2018 Apr;111(4):229-232. doi: 10.1016/j.acvd.2018.04.001. Epub 2018 Apr 17.
7
Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
JACC Cardiovasc Interv. 2017 Mar 13;10(5):477-485. doi: 10.1016/j.jcin.2016.11.034. Epub 2017 Feb 15.
8
Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease.
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.116.003978.
9
1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
JACC Cardiovasc Interv. 2016 Mar 14;9(5):440-9. doi: 10.1016/j.jcin.2015.10.042. Epub 2016 Jan 6.
10
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
Catheter Cardiovasc Interv. 2016 Sep;88(3):380-7. doi: 10.1002/ccd.26516. Epub 2016 Apr 1.
Zotero 插件